Advertisement
IQV vs TMO
Which Stock Would AI Choose? IQVIA Holdings (IQV) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- IQV has delivered stronger recent share price momentum, with gains exceeding 40% over the past year amid accelerating organic growth and AI-enabled service expansion.
- TMO offers broader exposure to life sciences tools and recurring consumables revenue, with Q2 2026 organic growth of 5% marking its strongest pace since 2021 and a raised full-year outlook.
- Both companies reported solid second-quarter results that exceeded expectations, supporting raised guidance and reflecting improving demand in the healthcare and life sciences sectors.
- IQV focuses on clinical research outsourcing, data analytics, and healthcare intelligence, while TMO provides instruments, reagents, and biopharma services across a wider scientific workflow.
- Analyst sentiment remains constructive for both, with IQV carrying a Moderate Buy consensus and TMO benefiting from institutional positioning amid sector recovery.
- Relative performance favors IQV on shorter-term momentum, whereas TMO provides scale and stability with a larger market capitalization.
Introduction
This comparison examines IQV and TMO, two established players in the life sciences and healthcare sectors. IQV specializes in clinical research services and data-driven insights, while TMO supplies essential tools, instruments, and services that support scientific discovery and biopharmaceutical development. Investors and traders seeking exposure to healthcare innovation, contract research, and laboratory infrastructure may find the relative performance, growth drivers, and market positioning of these stocks relevant when evaluating sector allocation or pair trades in the current environment.
IQV Overview and Recent Performance
IQV, or IQVIA Holdings Inc., operates as a global provider of clinical research services, commercial insights, and healthcare intelligence. Its business spans Research & Development Solutions, Technology & Analytics Solutions, and Contract Sales & Medical Solutions, leveraging extensive proprietary data and AI capabilities. In recent market activity, shares have shown notable strength, rising more than 40% over the past year and approximately 60% in the prior six months. The company reported second-quarter revenue of $4.37 billion, up 8.7% year over year, with adjusted earnings per share of $3.15 that exceeded expectations. Management raised full-year guidance, citing robust bookings and demand for AI-enabled analytics. Recent institutional activity and a $2 billion senior notes offering reflect ongoing capital management amid a favorable backdrop for clinical outsourcing.
TMO Overview and Recent Performance
TMO, or Thermo Fisher Scientific Inc., serves as a leading supplier of life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services. Its diversified model emphasizes recurring revenue from consumables and services across pharmaceutical, biotech, academic, and industrial end markets. In recent market activity, shares have advanced amid improving customer demand, with second-quarter revenue reaching $11.99 billion, up 10% year over year including 5% organic growth—the strongest pace since 2021. Adjusted earnings per share of $6.03 surpassed consensus estimates, prompting management to raise its 2026 outlook. The company has executed share repurchases and portfolio optimization, including the divestiture of its microbiology business, while highlighting expanding biopharma activity and AI-driven opportunities in its instrumentation platforms.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots designed for various market conditions. Tickeron offers hundreds of AI Trading Bots that trade thousands of different tickers, yet only the best and most suitable for current market conditions earn placement in this section. Available bots feature a wide range of performance statistics, with many demonstrating win rates between 55% and 75% alongside varying risk metrics and holding periods. These systems employ distinct trading styles, strategies, and timeframes while covering diverse sets of tickers. The platform provides transparent historical performance data to help users evaluate options aligned with their objectives. Explore the full selection at Trending AI Robots.
Head-to-Head Comparison
IQV and TMO differ in business focus and scale. IQV centers on outsourced clinical development and data analytics, generating revenue primarily through service contracts and technology subscriptions that benefit from high switching costs. TMO emphasizes a broader “picks-and-shovels” role, supplying instruments and consumables with substantial recurring revenue streams across research and production workflows. Recent momentum has favored IQV on share-price appreciation tied to earnings beats and AI adoption, while TMO has demonstrated resilience through organic growth recovery and operational execution. Risk factors include regulatory pressures on clinical trials for IQV and cyclical biopharma spending for TMO. Sector exposure overlaps in life sciences yet diverges in direct service versus enabling infrastructure, creating distinct trade-offs in growth visibility and margin stability.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings momentum, and relative positioning, Tickeron’s AI models currently assign a modestly higher probability of favorable near-term performance to IQV. Stronger recent share-price appreciation, accelerating organic growth, and AI-driven service differentiation provide clearer catalysts compared with TMO’s more measured recovery trajectory. That said, TMO’s larger scale, recurring revenue base, and raised guidance support a balanced outlook with lower volatility potential. The assessment remains probabilistic and reflects current market data rather than any guarantee of future results.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IQV is a Hold and TMO is a Buy.
IQV | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 19 | 29 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 65 Fair valued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 94 | 70 | |
SMR RATING 1..100 | 43 | 60 | |
PRICE GROWTH RATING 1..100 | 14 | 23 | |
P/E GROWTH RATING 1..100 | 22 | 19 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (13) in the Medical Specialties industry is somewhat better than the same rating for IQV (65) in the Servicestothe Health Industry industry. This means that TMO’s stock grew somewhat faster than IQV’s over the last 12 months.
TMO's Profit vs Risk Rating (70) in the Medical Specialties industry is in the same range as IQV (94) in the Servicestothe Health Industry industry. This means that TMO’s stock grew similarly to IQV’s over the last 12 months.
IQV's SMR Rating (43) in the Servicestothe Health Industry industry is in the same range as TMO (60) in the Medical Specialties industry. This means that IQV’s stock grew similarly to TMO’s over the last 12 months.
IQV's Price Growth Rating (14) in the Servicestothe Health Industry industry is in the same range as TMO (23) in the Medical Specialties industry. This means that IQV’s stock grew similarly to TMO’s over the last 12 months.
TMO's P/E Growth Rating (19) in the Medical Specialties industry is in the same range as IQV (22) in the Servicestothe Health Industry industry. This means that TMO’s stock grew similarly to IQV’s over the last 12 months.
| IQV | TMO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 68% | 2 days ago 62% |
| Stochastic ODDS (%) | 2 days ago 69% | 2 days ago 65% |
| Momentum ODDS (%) | 2 days ago 62% | 2 days ago 64% |
| MACD ODDS (%) | 2 days ago 76% | 2 days ago 73% |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 62% |
| TrendMonth ODDS (%) | 2 days ago 68% | 2 days ago 62% |
| Advances ODDS (%) | 3 days ago 63% | 8 days ago 62% |
| Declines ODDS (%) | 16 days ago 65% | 17 days ago 62% |
| BollingerBands ODDS (%) | 4 days ago 64% | 2 days ago 54% |
| Aroon ODDS (%) | 2 days ago 61% | 2 days ago 60% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IQV’s FA Score shows that 2 FA rating(s) are green while TMO’s FA Score has 3 green FA rating(s).
- IQV’s FA Score: 2 green, 3 red.
- TMO’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IQV’s TA Score shows that 3 TA indicator(s) are bullish while TMO’s TA Score has 5 bullish TA indicator(s).
- IQV’s TA Score: 3 bullish, 5 bearish.
- TMO’s TA Score: 5 bullish, 4 bearish.
Price Growth
IQV (@Medical Specialties) experienced а -0.36% price change this week, while TMO (@Medical Specialties) price change was +2.60% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +2.92%. For the same industry, the average monthly price growth was +7.79%, and the average quarterly price growth was +60.79%.
Reported Earning Dates
IQV is expected to report earnings on Nov 04, 2026.
TMO is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Medical Specialties (+2.92% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
IQV and
Correlation & Price change
A.I.dvisor indicates that over the last year, IQV has been closely correlated with CRL. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if IQV jumps, then CRL could also see price increases.